Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJohnson Matthey Regulatory News (JMAT)

Share Price Information for Johnson Matthey (JMAT)

Share Price is delayed by 15 minutes
Get Live Data
2,080.00    -62.00 (-2.89%)
Bid:
2,066.00
Ask:
2,070.00
Spread: 4.00 (0.194%)
Market Cap: £3.48b
JMAT Live PriceLast checked at - London Stock Exchange

Intraday Johnson Matthey Share Chart

Update on Catalyst Technologies sale

23 Feb 2026 07:00

RNS Number : 9927T
Johnson Matthey PLC
23 February 2026
 

23rd February 2026

 

Johnson Matthey Plc

(the Company)

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

Transaction update

On 22nd May 2025, Johnson Matthey Plc ("JM") and Honeywell International, Inc. ("Honeywell") announced an agreement to sell JM's Catalyst Technologies business ("CT") to Honeywell (the "Transaction").

JM and Honeywell have agreed to extend the long stop date for satisfaction of the closing conditions (the "Long Stop Date") from 21st February to 21st July 2026. In the event that the only remaining antitrust approval condition is not satisfied by the Long Stop Date, the Long Stop Date may be further extended to 21st August 2026, if certain conditions are met. JM and Honeywell expect to complete the Transaction by the end of August 2026.

In agreeing to extend the Long Stop Date, JM and Honeywell have also agreed to amend the financial terms of the Transaction to reflect CT's business performance during 2025/26, which includes the deferral of key sustainable solutions licensing projects and reduced profitability from the supply of catalysts due to the challenging market environment. Accordingly, JM has agreed to sell the CT business to Honeywell for an enterprise value of £1,325 million on a cash and debt-free basis.

Consequently, JM now expects to return c.£1,000 million of net sale proceeds to its shareholders following completion of the Transaction, comprising £800 million through a special dividend with share consolidation, and £200 million through an on-market share buyback programme.

JM continues to make good progress on the implementation of its new cash-focused business model and is on track to deliver 2025/26 performance in line with guidance. This includes group underlying operating profit growth at the higher end of a mid single digit percentage range¹, and positive free cash flow that is materially higher than last year².

The person responsible for the release of this announcement is Simon Price, General Counsel and Company Secretary of JM.

ENDS

 

Enquiries: 

Investor Relations

 

 

Louise Curran

Head of Investor Relations

+44 20 7269 8235

Media

Sinead Keller

Guy Bates 

Group External Relations Director

Kekst CNC

+44 20 7269 8218

+44 7581 056 415

 

Johnson Matthey Plc is listed on the London Stock Exchange (JMAT)

Registered in England & Wales number: 00033774Legal Entity Identifier number: 2138001AVBSD1HSC6Z10

 

Notes:

1.

Underlying operating profit is on a pro forma basis excluding CT and Value Businesses, and at constant precious metal prices and constant currency. 

2.

Free cash flow defined as net cash flow from operating activities (excluding disposal related costs) after net interest paid, net purchases of non-current assets and investments and the principal elements of lease payments, adjusted to reflect the classification of Catalyst Technologies as a discontinued operation. 2024/25: £64 million inflow.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURXLLLLQLLEBBF
Date   Source Headline
3rd Jun 20269:03 amRNSDirector/PDMR Shareholding
2nd Jun 20264:40 pmRNSDirector/PDMR Shareholding
1st Jun 20264:02 pmRNSHolding(s) in Company
28th May 20267:05 amRNSBoard Changes
28th May 20267:01 amRNSJohnson Matthey acquisition of Cormetech
28th May 20267:00 amRNSJohnson Matthey Full Year Results
14th May 202611:42 amRNSDirector/PDMR Shareholding
16th Apr 202611:51 amRNSDirector/PDMR Shareholding
24th Mar 202611:30 amRNSDirector/PDMR Shareholding
27th Feb 20267:00 amRNSDirector Declaration
24th Feb 20263:30 pmRNSDirector/PDMR Shareholding
24th Feb 20269:48 amRNSDirector/PDMR Shareholding
23rd Feb 20265:19 pmRNSDirector/PDMR Shareholding
23rd Feb 20267:00 amRNSUpdate on Catalyst Technologies sale
12th Feb 202612:44 pmRNSDirector/PDMR Shareholding
14th Jan 20262:22 pmRNSDirector/PDMR Shareholding
8th Jan 202610:01 amRNSHolding(s) in Company
30th Dec 20257:00 amRNSHolding(s) in Company
29th Dec 20257:00 amRNSHolding(s) in Company
29th Dec 20257:00 amRNSHolding(s) in Company
11th Dec 20254:51 pmRNSDirector/PDMR Shareholding
20th Nov 20257:00 amRNSDirectorate change
20th Nov 20257:00 amRNSJohnson Matthey Half Year Results
13th Nov 20257:00 amRNSDirector/PDMR Shareholding
24th Oct 202511:29 amRNSHolding(s) in Company
21st Oct 20253:44 pmRNSHolding(s) in Company
13th Oct 202511:55 amRNSDirector/PDMR Shareholding
9th Oct 20257:00 amRNSFinancial reporting structure and trading update
3rd Oct 202510:23 amRNSHolding(s) in Company
30th Sep 20257:00 amRNSHolding(s) in Company
26th Sep 20255:29 pmRNSHolding(s) in Company
17th Sep 20259:00 amRNSDirector Declaration
15th Sep 20252:37 pmRNSHolding(s) in Company
11th Sep 20254:13 pmRNSDirector/PDMR Shareholding
8th Sep 20256:00 pmRNSHolding(s) in Company
4th Sep 20255:19 pmRNSHolding(s) in Company
2nd Sep 20254:07 pmRNSHolding(s) in Company
29th Aug 202512:05 pmRNSTotal Voting Rights
26th Aug 20252:07 pmRNSDirector/PDMR Shareholding
13th Aug 20254:38 pmRNSDirector/PDMR Shareholding
13th Aug 20251:51 pmRNSDirector/PDMR Shareholding
5th Aug 20255:19 pmRNSHolding(s) in Company
5th Aug 20254:50 pmRNSDirector/PDMR Shareholding
25th Jul 20252:12 pmRNSHolding(s) in Company
23rd Jul 20252:23 pmRNSHolding(s) in Company
18th Jul 202512:07 pmRNSDirector/PDMR Shareholding
18th Jul 20259:18 amRNSHolding(s) in Company
17th Jul 20252:20 pmRNSResult of AGM
17th Jul 20257:00 amRNSAppointment of Andrew Cosslett as Chair
9th Jul 20254:48 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.